Keytruda Is First Checkpoint Inhibitor To Get Approval for Front Line NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

KEYTRUDA (pembrolizumab) received FDA approval for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login